ライフサイエンスコーパス: vaccinia virus

1 scent formation, including the A6 protein of vaccinia virus.

2 merous RNA viruses but enhances the entry of vaccinia virus.

3 ized against foreign rhesus D alloantigen or vaccinia virus.

4 the movement of microbial pathogens such as vaccinia virus.

5 athway components for cell-to-cell spread of vaccinia virus.

6 mory CD8(+) T cells following infection with vaccinia virus.

7 sing data from humans, domestic pigeons, and vaccinia virus.

8 the crystal structure of the H7 protein from vaccinia virus.

9 g during a severe respiratory infection with vaccinia virus.

10 uitment of leukocytes, which is unique among vaccinia viruses.

11 ll function in the lung after infection with vaccinia virus, a member of the Poxviridae family.

12 immune-deficient (nu/nu) mice infected with vaccinia virus, a model of smallpox.

13 at causes a persistent/latent infection, and vaccinia virus, a poxvirus that is cleared by the host.

14 The vaccinia virus A56 and K2 proteins in the cell membrane

15 In this study, we uncovered a means of vaccinia virus adaptation involving the accumulation of

16 e-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection, to

17 res of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplified by the m

18 steria monocytogenes, Shigella flexneri, and Vaccinia virus among other pathogens use the same common

19 es of fatty acid in the diet on infection by vaccinia virus, an acute infection that begins in the re

20 It is not enriched for vaccinia virus and Candida albicans-MP65 (immunodominant

21 oping potent neutralizing antibodies against vaccinia virus and comprehensively characterizing their

22 e membrane-wrapping step in morphogenesis of vaccinia virus and egress from the cell.

23 panied by increased viral resistance against vaccinia virus and influenza B virus infections.

24 res are also induced by two other pathogens (vaccinia virus and Listeria monocytogenes).

25 its actin polymerization downstream of EPEC, Vaccinia virus and opsonized red blood cells.

26 Efficient cell-to-cell spread of vaccinia virus and other orthopoxviruses depends on the

27 bisbenzimide derivatives are potent against vaccinia virus and other poxviruses but ineffective agai

28 Vaccinia virus and other poxviruses encode enzymes for b

29 This discovery identifies a weakness of vaccinia virus and suggests a possible direction to inte

30 bility to monkeypox virus, cowpox virus, and vaccinia virus and thus providing a unique model for stu

31 r of the Orthopoxvirus genus, which includes Vaccinia virus and Variola virus (the causative agent of

32 rus is intermediate in pathogenicity between vaccinia virus and variola virus.

33 vo from mRNA synthesized in the cytoplasm by vaccinia virus, and hence cannot be spliced.

34 uses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interfer

35 by extensively passaging the chorioallantois vaccinia virus Ankara (CVA) vaccine strain in chicken em

36 uential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens,

37 The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenoviru

38 impanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in

39 Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we chara

40 A DNA prime-modified vaccinia virus Ankara (MVA) boost vaccine has proven to

41 nuclear antigen EBNA1 followed by a modified vaccinia virus Ankara (MVA) booster, induced significant

42 priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on viru

43 Modified vaccinia virus Ankara (MVA) is a safe and well-character

44 asal administration of the poxvirus modified vaccinia virus Ankara (MVA) is sufficient to induce high

45 ctors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer o

46 we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency viru

47 M1L is absent in the attenuated modified vaccinia virus Ankara (MVA) strain of VACV, a strain tha

48 We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosai

49 DCs or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector, improved priming of

50 ic cellular immune responses to the modified vaccinia virus Ankara (MVA) vector.

51 ity to both insert Ag85A and vector modified vaccinia virus Ankara (MVA) was assessed by ex-vivo inte

52 The poxvirus strain modified vaccinia virus Ankara (MVA), a safe and efficient viral

53 Modified vaccinia virus Ankara (MVA), a widely used vaccine vecto

54 Modified vaccinia virus Ankara (MVA), an attenuated poxvirus, has

55 with different combinations of DNA, modified vaccinia virus Ankara (MVA), soluble gp140 protein, and

56 ific T cells induced by a DNA-prime modified vaccinia virus Ankara (MVA)-boost vaccination strategy,

57 ency virus (SHIV) and boosting with modified vaccinia virus Ankara (MVA)-SHIV vaccines in rhesus maca

58 onserved antigenic regions by using modified vaccinia virus Ankara (MVA).

59 sized and cloned into a recombinant modified vaccinia virus Ankara (MVA).

60 /IL-15, SIV Gag/Pol/Env recombinant modified vaccinia virus Ankara (rMVA), and AT-2 SIVmac239 inactiv

61 f a candidate tuberculosis vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), i

62 mine if mucosal vaccination using a modified vaccinia virus Ankara expressing human immunodeficiency

63 We show that booster modified vaccinia virus Ankara immunization induced a distinct an

64 e questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140

65 V S and core antigen, followed by a modified Vaccinia virus Ankara vector to induce HBV-specific B- a

66 r SIVmac239 envelope-expressing DNA/modified vaccinia virus Ankara vector- and protein-based vaccinat

67 ectors, using simian adenovirus and modified vaccinia virus Ankara vectors.

68 far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular sto

69 impanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C,

70 ized with SIVmac239-based DNA-prime/modified vaccinia virus Ankara-boost vaccine regimens that includ

71 from rabbits and RM given identical modified vaccinia virus Ankara-prime/gp120-boost immunization reg

72 ther a chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a mult

73 second homologous immunization with modified vaccinia virus Ankara.

74 f this homolog during infection, we utilized vaccinia virus as a surrogate and showed that a vaccinia

75 as been developed using the immunogenic live vaccinia virus as a vaccine vector, expressing multiple

76 protein toxins, potently prevented spread of vaccinia virus as well as monkeypox virus, a human patho

77 ures of core and complete vRNAP enzymes from Vaccinia virus at 2.8 angstrom resolution.

78 we present the crystal structure of H3 from vaccinia virus at a 1.9-A resolution.

79 and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and induces PD-

80 t that dynamic phosphorylation involving the vaccinia virus B1 kinase and cellular enzymes is likely

81 The vaccinia virus B1 kinase is highly conserved among poxvi

82 The most well characterized role for the vaccinia virus B1 kinase is to facilitate viral DNA repl

83 The vaccinia virus B1 protein is a homolog of cellular vacci

84 The vaccinia virus B1 protein kinase is involved in promotin

85 This study focuses on the vaccinia virus B1 protein kinase, an enzyme that promote

86 viously characterized functions, B1 inhibits vaccinia virus B12 protein via a phosphorylation-depende

87 /182R with a functional version derived from vaccinia virus, B13R Our results show that MVA-B13R sign

88 HIV-1 antigens, with one of them lacking the vaccinia virus B19 protein, an inhibitor of the type I i

89 The vaccinia virus B1R gene encodes a highly conserved prote

90 TRAP is delivered using adenovirus- and vaccinia virus-based vectors in a prime-boost regime.

91 Although superinfecting vaccinia virus bound to cells, infection was inhibited a

92 onocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in the case of mouse cyt

93 gression are arrested in cells infected with vaccinia virus, but mass fluctuations continue until cel

94 uperinfection exclusion may be beneficial to vaccinia virus by selecting particles that can infect ce

95 host-range proteins that share homology with vaccinia virus C7 protein.

96 red improved protection against Listeria and vaccinia virus challenges compared with the Armstrong bo

97 Thus, vDeltaK1L is the first vaccinia virus construct reported that caused a muted in

98 ispensable for determining the mechanisms of vaccinia virus core-directed transcription.

99 Thus, vaccinia virus decapping, in addition to targeting mRNAs

100 n a murine model of cutaneous infection with vaccinia virus, dermal gammadelta T cell numbers increas

101 nsight into the role of D4 as a co-factor of vaccinia virus DNA polymerase and allows a better unders

102 Vaccinia virus early genes are transcribed immediately u

103 Because vaccinia virus early transcription is coupled to the vir

104 virion preparations, >88% of the theoretical vaccinia virus-encoded proteome was detected with high c

105 Vaccinia virus encodes three BTB-Kelch proteins: A55, C2

106 EPD of vaccinia virus encoding OVA induced significantly higher

107 gainst intranasal challenge with recombinant vaccinia virus encoding p24.

108 peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mi

109 e isolation and characterization of numerous vaccinia virus enzymes, determination of the cap structu

110 cinia virus as a surrogate and showed that a vaccinia virus expressing MC021L-HA in place of F13L-HA

111 Comparison of responses to vaccinia virus expressing OVA peptide SIINFEKL by wild-t

112 vides complete immune control of recombinant vaccinia virus expressing the same epitope if KCSRNRQYL

113 with a small-plaque phenotype.IMPORTANCE The vaccinia virus extracellular virion protein F13 is requi

114 aa 21-84), a recombinant envelope protein of vaccinia virus, for glycosaminoglycans (GAGs)-specific t

115 ed RNA start sites have made the analysis of vaccinia virus gene expression challenging.

116 rhtrs1-amplified viruses, there arose in two vaccinia virus genes mutations that improved viral repli

117 n and conferred CD8-mediated protection to a vaccinia virus genital challenge.

118 ed interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma c

119 fficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodium iodide

120 ORTANCE Previous studies have shown that the vaccinia virus glycoproteins A34 and B5 interact, and in

121 omologs of the Bcl-2 family of proteins, and vaccinia virus harbors antiapoptotic F1L that potently i

122 The smallpox vaccine using vaccinia virus has been highly successful, but it is sti

123 giosum virus, is predicted to encode several vaccinia virus homologs of EV-specific proteins, includi

124 modified by the insertion of the K1L and C7L vaccinia virus host range genes and express the clade C(

125 per by applying it to SIM and STED images of vaccinia virus in isolation and when engaged with host c

126 ges in the cytoskeleton, studies with mutant vaccinia viruses indicated that the cytoskeletal changes

127 RNAs were translationally upregulated during vaccinia virus-induced host protein synthesis shutoff.

128 ured the host mRNA translation rate during a vaccinia virus-induced host shutoff by analyzing total a

129 ns may be selectively synthesized during the vaccinia virus-induced host shutoff.

130 s rapidly and preferentially associated with vaccinia virus-infected cells in the LN paracortex, whic

131 , we analyzed the responses of host cells to vaccinia virus infection at both the transcriptional and

132 minor groove of double-stranded DNA, inhibit vaccinia virus infection by blocking viral DNA replicati

133 This study highlights the fact that vaccinia virus infection can enhance cellular energy pro

134 Vaccinia virus infection causes a host shutoff that is m

135 Using a model of respiratory vaccinia virus infection in mice, we could specifically

136 In this study, with vaccinia virus infection in mice, we show that OX40 was

137 dependent of infection or during a surrogate vaccinia virus infection to identify how MC159 prevented

138 infection with either virus, after a cleared vaccinia virus infection, and during a persistent/latent

139 f oxidative phosphorylation increased during vaccinia virus infection, while inhibition of the cellul

140 cific CD8(+) T cells responses to subsequent vaccinia virus infection.

141 regulation of the CD8(+) T cell response to vaccinia virus infection.

142 ncreased and accelerated mortality following vaccinia virus infection.

143 most bone marrow T cells activate 3 d after vaccinia virus infection.

144 dly increase translation in the first day of vaccinia virus infection.

145 LECs toward MPECs, during the acute phase of vaccinia virus infection.

146 ty to localize infected cells and to control vaccinia virus infection.

147 which accelerates clearance of epicutaneous vaccinia virus infection.

148 e ability to act as a potent defense against vaccinia virus infection.

149 mune detection pathways, we performed serial vaccinia virus infections in primary human cells.

150 The achieved LOD for vaccinia virus is 10(4) particles in 1 mL of sample.

151 Vaccinia virus is a powerful model to study antibody res

152 nd vaccination of patients with AD with live vaccinia virus is contraindicated because of a heightene

153 present evidence that the impact of VRK2 on vaccinia virus is largely independent of BAF phosphoryla

154 Here, we show that the membrane of vaccinia virus is organized into distinct functional dom

155 on, and in the case of influenza B virus and vaccinia virus, ISG15 conjugation has been shown to rest

156 Until now, all known rifampin-resistant vaccinia virus isolates have contained missense mutation

157 On the basis of these results, vaccinia virus keratitis is significantly different from

158 We found a site in vaccinia virus L1 protein as the target of a group of hi

159 factor (IRF) activation and ISG responses to vaccinia virus lacking F17 in both macrophages and lung

160 nd D10, but not of either enzyme alone, halt vaccinia virus late protein synthesis and inhibit virus

161 that B1 is required at another stage of the vaccinia virus life cycle.

162 Thus, vaccinia virus makes novel use of the retrograde transpo

163 sion in other viral systems, did not prevent vaccinia virus membrane fusion, suggesting that these in

164 Upon infections with Toxoplasma gondii and vaccinia virus, mice with stabilized DC beta-catenin dis

165 revealed that this protein is essential for vaccinia virus morphogenesis and that its absence result

166 of high-pressure freezing in preserving the vaccinia virus nucleocapsid.

167 We characterized a mouse model of vaccinia virus ocular disease using C57BL/6 mice and str

168 fected cells after administration to mice of vaccinia virus or Zika virus.

169 of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive variant of the

170 mass spectrometry to identify more than 170 vaccinia virus pMHCI presented on infected mouse cells.

171 Vaccinia virus polymerase holoenzyme is composed of the

172 Crystal structures of vaccinia virus poxin in pre- and post-reactive states de

173 adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination).

174 t rabbits immunized with a novel recombinant vaccinia virus prime-gp120 protein boost regimen generat

175 network is also assembled downstream of the Vaccinia virus protein A36 and the phagocytic Fc-gamma r

176 Vaccinia virus protein A49 inhibits NF-kappaB activation

177 described a novel role for B1 in inhibiting vaccinia virus protein B12, which otherwise impedes an e

178 We now demonstrate that the vaccinia virus protein F11, which localizes to the plasm

179 logues from other poxviruses, but not in the vaccinia virus proteins C2 or F3.

180 Five conserved vaccinia virus proteins, referred to as Viral Membrane A

181 ide evidence for the phosphoglycosylation of vaccinia virus proteins.

182 l involving serial passages of an attenuated vaccinia virus, rapid acquisition of inactivating frames

183 n and luciferase reporters demonstrated that vaccinia virus recognized MOCV intermediate and late pro

184 ia virus B1 protein is a homolog of cellular vaccinia virus-related kinases (VRKs) and is needed for

185 xhibits a remarkable degree of similarity to vaccinia virus-related kinases (VRKs), a family of cellu

186 g of three conserved cellular enzymes called vaccinia virus-related kinases (VRKs).

187 depend on host cells to provide, to support vaccinia virus replication during a host shutoff.IMPORTA

188 iscovered that TRAF2 is a proviral factor in vaccinia virus replication in both HeLa cells and mouse

189 deletion of the poxin gene (B2R) attenuates vaccinia virus replication in vivo.

190 the beginning of the 1980s, research on the vaccinia virus replication mechanism has basically stall

191 horylation function significantly suppressed vaccinia virus replication.

192 ilability plays a critical role in efficient vaccinia virus replication.

193 rce to fuel the tricarboxylic acid cycle for vaccinia virus replication.

194 maintenance of its function is important for vaccinia virus replication.

195 lysis, we found that the fusion machinery of vaccinia virus resides exclusively in clusters at virion

196 Vaccinia virus ribosome-associated mRNA sequences were d

197 perator sequence) into oncolytic recombinant vaccinia viruses (rVACV), which were further characteriz

198 ss-of-function analysis, we demonstrate that vaccinia virus's dependence on VRK2 is only observed in

199 Poxviruses, myxoma virus and vaccinia virus specifically, utilize a virus-encoded hos

200 measured after anti-CD3 stimulation or after vaccinia virus stimulation to measure T cells elicited a

201 The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved r

202 ion-competent, attenuated recombinant of the vaccinia virus strain NYVAC.

203 ection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis, corneal

204 e B21/22 family glycoproteins not encoded by vaccinia virus strains used as vaccines.

205 In this study, we show across a range of vaccinia virus strains, including the current clonal sma

206 more resistant to respiratory infection with vaccinia virus than wild-type mice.

207 l Medicine, Park et al. develop an oncolytic vaccinia virus that introduces truncated CD19 expression

208 ved in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.

209 Vaccinia virus, the live vaccine for smallpox, is one of

210 Vaccinia virus, the prototypic member of the poxviruses,

211 When compared to vaccinia virus, this archival strain contained the same

212 antiviral protein PKR, enabled a recombinant vaccinia virus to replicate in resistant cells from huma

213 here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment is a conse

214 During its egress, vaccinia virus transiently recruits AP-2 and clathrin af

215 uct a high-resolution genome-wide map of the vaccinia virus translatome.

216 irst-ever use of tecovirimat as a preemptive vaccinia virus treatment strategy during induction chemo

217 e inhibitor 1 (SPI-1) of rabbitpox virus and vaccinia virus, two closely related orthopoxviruses, pre

218 First, we demonstrate that vaccinia virus uniquely requires VRK2 for viral replicat

219 of aggressive melanomas induced by oncolytic Vaccinia virus using RNA sequencing and found substantia

220 Vaccinia virus (VACV) A27 is a target for viral neutrali

221 The vaccinia virus (VACV) A56/K2 fusion regulatory complex a

222 tions that (i) the replication and spread of vaccinia virus (VACV) and herpes simplex virus type 1 (H

223 Using vaccinia virus (VACV) as a model organism for other Orth

224 In this study, we applied vaccinia virus (VACV) by scarification to IL-1R1 knockou

225 Vaccinia virus (VACV) continues to be used in immunother

226 produced in excess in cells infected with a vaccinia virus (VACV) decapping enzyme mutant and by wil

227 Vaccinia virus (VACV) decapping enzymes and cellular exo

228 The vaccinia virus (VACV) E3 protein has been shown to be im

229 Vaccination with vaccinia virus (VACV) elicits heterotypic immunity to sm

230 The I2L open reading frame of vaccinia virus (VACV) encodes a conserved 72-amino-acid

231 Vaccinia virus (VACV) encodes an innate immune evasion p

232 The poxvirus vaccinia virus (VACV) encodes numerous inhibitors of NF-

233 Vaccinia virus (VACV) encodes several proteins that inhi

234 Vaccinia virus (VacV) encodes two decapping enzymes (D9,

235 Vaccinia virus (VACV) envelope protein D8 is one of thre

236 Vaccinia virus (VACV) evades the host immune response by

237 This work reveals the prototypic poxvirus Vaccinia virus (VACV) exploits cellular retrograde trans

238 ses; instead, we identified mutations in two vaccinia virus (VACV) genes, A24R and A35R, either of wh

239 have determined the crystal structure of the vaccinia virus (VACV) H7 protein.

240 assessed several routes of immunization with vaccinia virus (VACV) in protecting mice against ectrome

241 ically defined T cell epitopes recognized in vaccinia virus (VACV) infected C57BL/6 mice (expressing

242 This study investigates how vaccinia virus (VACV) infection alters global cellular m

243 -knockout CD8(+) TRM cells generated by skin vaccinia virus (VACV) infection were less effective at p

244 In establishing a respiratory infection, vaccinia virus (VACV) initially replicates in airway epi

245 Vaccinia virus (VACV) is a member of the Poxviridae fami

246 Vaccinia virus (VACV) is a poxvirus, and the VACV D4 pro

247 Vaccinia virus (VACV) is a useful model system for under

248 Skin scarification (s.s.) with vaccinia virus (VACV) is essential for generation of an

249 The vaccinia virus (VACV) K1 protein has multiple immunomodu

250 elicited protective immunity.IMPORTANCE The vaccinia virus (VACV) K1 protein inhibits NF-kappaB acti

251 Vaccinia virus (VACV) keratitis is a serious complicatio

252 Vaccinia virus (VACV) L1 is an important target for vira

253 The vaccinia virus (VACV) M1 ankyrin (ANK) protein, a protei

254 f a novel apoptosis inhibitor encoded by the vaccinia virus (VACV) M1L gene.

255 Vaccinia virus (VACV) provides the backbone for some of

256 PKRs were able to restrict replication of a vaccinia virus (VACV) strain that lacks the PKR inhibito

257 high-throughput RNAi screen directed against vaccinia virus (VACV) to identify the VACV AAA+ ATPase D

258 Oxford Nanopore Technologies to profile the vaccinia virus (VACV) transcriptome.

259 Poxviruses such as Vaccinia virus (VACV) undertake a complex cytoplasmic re

260 The 50% lethal intraperitoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas B

261 Vaccinia virus (VACV), a close relative of smallpox viru

262 virus (ECTV), a natural mouse pathogen, and vaccinia virus (VACV), a heterologous virus that neverth

263 arly every step in the reproductive cycle of vaccinia virus (VACV), a large DNA virus with about 200

264 Vaccinia virus (VACV), the prototype member of the poxvi

265 n of proteins on nascent DNA) to investigate vaccinia virus (VACV), the prototype poxvirus.

266 y plasmid can replicate in cells infected by vaccinia virus (VACV), the prototype poxvirus.

267 Vaccinia virus (VACV), the prototypical member of the po

268 Using vaccinia virus (VACV), the smallpox vaccine, we report t

269 Yet, in the case of vaccinia virus (VACV), which constitutes the vaccine use

270 We used vaccinia virus (VACV)--a gold standard vaccine--as the i

271 Using skin infections with vaccinia virus (VacV)-expressing model antigens, we foun

272 are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how

273 utations during serial passage of attenuated vaccinia virus (VACV).

274 ient (nude, nu/nu) BALB/c mice infected with vaccinia virus (VACV).

275 e immunity to a number of viruses, including vaccinia virus (VACV).

276 in the replication of the prototype poxvirus vaccinia virus (VACV).

277 lymphocytic choriomeningitis virus (LCMV) or vaccinia virus (VACV).

278 ted only to exhibit abortive infections with vaccinia virus (VACV).

279 ster ovary (CHO) cells are nonpermissive for vaccinia virus (VACV).

280 ed among poxviruses, including A6 and A11 of vaccinia virus (VACV).

281 EdU) into nascent DNA in cells infected with vaccinia virus (VACV).

282 ccination program using different strains of vaccinia virus (VACV; Poxviridae).

283 Vaccinia virus (VACV; the prototype poxvirus) prefers gl

284 We determined that a K1L-less vaccinia virus (vDeltaK1L) was less pathogenic than wild

285 deep study of the covalent structure of the vaccinia virus virion using the various tools of contemp

286 xamine the protein covalent structure of the vaccinia virus virion.

287 e epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin.

288 Here, we show that after resolution of skin vaccinia virus (VV) infection, antigen-specific circulat

289 Epicutaneous vaccinia virus (VV) infection, mimicking human smallpox

290 hocytic Choriomeningitis Virus (LCMV) WE and Vaccinia Virus (VV) infections with naive T(regs), we ob

291 ll responses were measured after anti-CD3 or vaccinia virus (VV) stimulation to measure T cells elici

292 Chimpanzee adenovirus-6 (AdC6) or -7 (AdC7), Vaccinia virus (VV), and DNA given by electroporation (D

293 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce immunogen

294 y 10 passage rounds, the starting attenuated vaccinia virus was displaced by viruses with one fixed m

295 Vaccinia virus was made famous by being the virus used i

296 We showed that superinfection by vaccinia virus was prevented at the membrane fusion step

297 From our work with vaccinia virus, we give first insights into the overall

298 ymphocytic choriomeningitis virus (LCMV) and vaccinia virus, where the pathogens are cleared, but it

299 sease is induced by intradermal injection of vaccinia virus, whereas a protective response occurs wit

300 , we replaced the F13L open reading frame in vaccinia virus with an epitope-tagged version of MC021L.